Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer

S Nagar, RP Remmel - Oncogene, 2006 - nature.com
The uridine diphosphoglucuronosyltransferases (UGTs) belong to a superfamily of enzymes
that catalyse the glucuronidation of numerous endobiotics and xenobiotics. Several human …

Genetic variability in CYP2A6 and the pharmacokinetics of nicotine

JC Mwenifumbo, RF Tyndale - 2007 - Taylor & Francis
Nicotine is the psychoactive substance responsible for tobacco dependence. It is also a
therapeutic used to aid smoking cessation. Cytochrome P450 (CYP) 2A6 is the human …

The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy

MI Gulcebi, A Ozkaynakcı, MZ Goren, RG Aker… - Epilepsy research, 2011 - Elsevier
Lamotrigine (LTG) which has a widespread use in epilepsy treatment as an antiepileptic
agent is metabolized by UDP-glucuronosyl transferase (UGT) enzymes. In this study, single …

Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation

M Nakajima, T Yokoi - Drug metabolism and pharmacokinetics, 2005 - jstage.jst.go.jp
Nicotine has roles in the addiction to smoking, replacement therapy for smoking cessation,
as a potential medication for several diseases such as Parkinson's disease, Alzheimer's …

The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia …

M Nozawa, T Ohnuma, Y Matsubara… - Therapeutic drug …, 2008 - journals.lww.com
The monitoring of plasma olanzapine concentrations has been found to be an important and
useful tool for optimizing psychiatric treatment. The present study investigated the effect that …

Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine

M López, P Dorado, N Monroy, ME Alonso… - 2011 - degruyter.com
Patients treated with antiepileptic drugs can exhibit large interindividual variability in clinical
efficacy or adverse effects. This could be partially due to genetic variants in genes coding for …

PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics

T Mitra-Ghosh, SP Callisto, JK Lamba… - Pharmacogenetics …, 2020 - journals.lww.com
Background Lamotrigine is an antiseizure drug (ASD) which was approved by the US Food
and Drug Administration in 1994 to treat focal (partial) seizures, primary generalized tonic …

In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole

LK Kamdem, Y Liu, V Stearns… - British journal of …, 2010 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Anastrozole is primarily cleared by
hepatic metabolism via oxidative and conjugating enzymes. WHAT THIS STUDY ADDS• …

Variability and function of family 1 uridine-5′-diphosphate glucuronosyltransferases (UGT1A)

CP Strassburg, S Kalthoff, U Ehmer - Critical reviews in clinical …, 2008 - Taylor & Francis
The substrate spectrum of human UDP-glucuronosyltransferase 1A (UGT1A) proteins
includes the glucuronidation of non-steroidal anti-inflammatory drugs, anticonvulsants …

Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China

Y Chang, L Yang, M Zhang, SY Liu - European journal of clinical …, 2014 - Springer
Objective The pharmacokinetics of lamotrigine (LTG) varies significantly among individuals
and particularly among different ethnic groups. This is in part due to the presence of genetic …